Kenvue Inc. $KVUE Shares Bought by Infrastructure Capital Advisors LLC

Infrastructure Capital Advisors LLC raised its stake in Kenvue Inc. (NYSE:KVUE) by 435.6% in the 4th quarter, HoldingsChannel.com reports. The fund owned 136,259 shares of the company’s stock after purchasing an additional 110,819 shares during the period. Infrastructure Capital Advisors LLC’s holdings in Kenvue were worth $2,350,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also made changes to their positions in the business. Physician Wealth Advisors Inc. boosted its stake in shares of Kenvue by 67.5% during the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after buying an additional 618 shares during the period. Mill Creek Capital Advisors LLC boosted its stake in shares of Kenvue by 0.6% during the fourth quarter. Mill Creek Capital Advisors LLC now owns 124,213 shares of the company’s stock worth $2,143,000 after buying an additional 701 shares during the period. B & T Capital Management DBA Alpha Capital Management boosted its stake in shares of Kenvue by 0.3% during the fourth quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company’s stock worth $4,048,000 after buying an additional 712 shares during the period. Philip James Wealth Mangement LLC boosted its stake in shares of Kenvue by 5.5% during the fourth quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company’s stock worth $240,000 after buying an additional 726 shares during the period. Finally, IFG Advisory LLC boosted its stake in shares of Kenvue by 5.4% during the fourth quarter. IFG Advisory LLC now owns 15,051 shares of the company’s stock worth $260,000 after buying an additional 766 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Shares of NYSE:KVUE opened at $18.03 on Thursday. The company has a quick ratio of 0.70, a current ratio of 0.98 and a debt-to-equity ratio of 0.67. The company has a market cap of $34.61 billion, a P/E ratio of 21.21, a PEG ratio of 1.40 and a beta of 0.54. Kenvue Inc. has a 52 week low of $14.02 and a 52 week high of $22.87. The company has a 50-day moving average price of $17.49 and a 200 day moving average price of $17.56.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.05. The firm had revenue of $3.91 billion during the quarter, compared to the consensus estimate of $3.84 billion. Kenvue had a net margin of 10.61% and a return on equity of 20.81%. The firm’s revenue was up 4.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.24 earnings per share. Research analysts predict that Kenvue Inc. will post 1.16 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were given a $0.2075 dividend. The ex-dividend date was Wednesday, May 13th. This represents a $0.83 dividend on an annualized basis and a yield of 4.6%. Kenvue’s dividend payout ratio (DPR) is presently 97.65%.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. Barclays decreased their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a research note on Tuesday, April 14th. UBS Group decreased their target price on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research note on Tuesday, April 7th. Canaccord Genuity Group increased their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a research note on Wednesday, February 18th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research note on Friday, May 8th. Finally, Weiss Ratings upgraded shares of Kenvue from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday. One analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the company. According to data from MarketBeat.com, Kenvue presently has a consensus rating of “Hold” and a consensus target price of $19.33.

Insider Buying and Selling

In related news, General Counsel Matthew Orlando sold 38,491 shares of the firm’s stock in a transaction dated Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.59% of the stock is currently owned by insiders.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.